Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

EZH2 Gene Sequencing (Weaver Syndrome) – Genetic Test in UAE | 2800 AED | DHA Licensed

Executive Summary & Core Metrics

Executive Summary – Why Patients Trust Our EZH2 Test

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
  • Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
  • Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed genetic specialists.
  • Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This next-generation sequencing (NGS) test examines the entire coding region and splice sites of the EZH2 gene to identify pathogenic variants associated with Weaver syndrome (overgrowth-intellectual disability) and elevated cancer susceptibility.

Feature Our EZH2 NGS Test Sanger Sequencing (Limited)
Methodology Next-Generation Sequencing – full gene analysis (all exons, ± splice sites) Sanger sequencing of selected exons (hotspot coverage only)
Diagnostic Sensitivity 99.9% for all EZH2 pathogenic variants ~70–80% (misses novel or deep intronic variants)
Turnaround Time 3 to 4 weeks 3 to 5 weeks
Variant Classification ACMG/AMP 2025 guidelines with full in silico evidence Limited bioinformatic support

Physician Insight & Safety Protocols

Physician’s Note from Dr. Lina Osama Zaki Quteineh (Consultant Medical Genetics – DHA License: 9294403): “As your attending clinician, I want to underscore that this EZH2 test must be interpreted within the full clinical picture—a positive result confirms Weaver syndrome in a child with macrocephaly and developmental delay, while a negative result calls for further investigation of alternative diagnoses. Please remember that a test result does not define your child; it provides a roadmap to targeted management and surveillance. Never adjust or discontinue any prescribed medication, especially antiepileptics or growth-related therapies, without speaking to me first.”

Advisory: Medication Warning

⚠️ Important

Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of anti-seizure drugs or hormonal treatments can precipitate severe complications.

Exclusion Criteria & Emergency Red Flags

  • Exclusion: Inability to provide informed consent (adult/guardian); medically unstable condition requiring acute inpatient care.
  • Emergency Red Flags – Seek urgent medical attention if: Sudden increase in head circumference (>2 SD within weeks), new-onset seizures, loss of previously acquired developmental milestones, or signs of leukemia/lymphoma (unexplained bruising, pallor, fever).

Patient FAQ & Clinical Guidance

1. What is EZH2 gene sequencing and why is it performed?

NGS test that analyzes EZH2 gene for pathogenic variants causing Weaver syndrome and cancer risks. It is indicated for children with overgrowth, distinctive facial features, and developmental delay, as well as adults with suspected familial cancer syndromes linked to EZH2 mutations.

2. How accurate is the test for diagnosing Weaver syndrome?

With 99.9% diagnostic sensitivity for EZH2 mutations, this NGS test provides definitive confirmation in suspected Weaver syndrome. Our laboratory uses advanced bioinformatics pipelines and confirms all variants with orthogonal methods, ensuring the highest level of clinical validity.

3. Is the test suitable for children?

Yes, it can be performed for infants and children with parental consent in accordance with UAE health regulations. A simple blood draw is used; no sedation required, and pre-test genetic counseling is provided.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance: This test adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Facility licensed by DHA (License No. 1143).

Clinical & Logistical Metadata

Test Name EZH2 Gene Sequencing (Weaver Syndrome)
Price (AED) 2,800
Turnaround Time 3 to 4 weeks
Sample Type / Matrix Peripheral whole blood (EDTA tube) or extracted DNA
Methodology Used Next-Generation Sequencing (Illumina platform)
ICD-10-CM Code Q87.3 (Weaver syndrome)
LOINC Code 77649-1
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians